Allen Naomi E, Key Timothy J, Appleby Paul N, Travis Ruth C, Roddam Andrew W, Rinaldi Sabina, Egevad Lars, Rohrmann Sabine, Linseisen Jakob, Pischon Tobias, Boeing Heiner, Johnsen Nina Føns, Tjønneland Anne, Grønbaek Henning, Overvad Kim, Kiemeney Lambartus, Bueno-de-Mesquita H Bas, Bingham Sheila, Khaw Kay Tee, Tumino Rosario, Berrino Franco, Mattiello Amalia, Sacerdote Carlotta, Palli Domenico, Quirós José Ramón, Ardanaz Eva, Navarro Carmen, Larrañaga Nerea, Gonzalez Carlos, Sanchez Maria-José, Trichopoulou Antonia, Travezea Cryssoula, Trichopoulos Dimitrios, Jenab Mazda, Ferrari Pietro, Riboli Elio, Kaaks Rudolf
Cancer Research UK Epidemiology Unit, University of Oxford, Oxford OX3 7LF, United Kingdom.
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7. doi: 10.1158/1055-9965.EPI-06-1062.
Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer.
We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression.
The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3.
In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.
一些研究表明，血清胰岛素样生长因子（IGF）-I浓度升高与前列腺癌风险增加相关，尤其是与晚期前列腺癌风险增加相关。
在欧洲癌症与营养前瞻性调查的一项巢式病例对照研究中，我们分析了诊断前血清IGF-I和IGF结合蛋白-3（IGFBP-3）浓度与前列腺癌风险之间的关联。该研究包括630例前列腺癌新发病例和630例匹配的对照对象。使用条件逻辑回归计算与IGF-I和IGFBP-3浓度升高相关的前列腺癌风险的比值比及其95%置信区间（95%CI）。
血清肽浓度最高三分位数与最低三分位数相比，IGF-I导致的前列腺癌总风险为1.35（95%CI，0.99-1.82；P趋势=0.08），调整IGFBP-3后IGF-I残差导致的风险为1.39（95%CI，1.02-1.89；P趋势=0.12），IGFBP-3导致的风险为1.22（95%CI，0.92-1.64；P趋势=0.38），调整IGF-I后IGFBP-3残差导致的风险为1.01（95%CI，0.74-1.37；P趋势=0.75）。按疾病分期，肽类激素与前列腺癌的关联无显著差异，尽管血清IGF-I浓度与晚期疾病风险的关联略强；IGF-I最高三分位数与最低三分位数相比的比值比为1.65（95%CI，0.88-3.08；P趋势=0.21），调整IGFBP-3后的IGF-I为1.76（95%CI，0.92-3.40；P趋势=0.11）。
在这项大型巢式病例对照研究中，血清IGF-I浓度与前列腺癌风险无强关联，尽管结果与风险略有增加相符，尤其是晚期疾病；未观察到IGFBP-3与前列腺癌有关联。
